drugset

drugset / Trial / NCT05252533

A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis

NCT05252533 ↗

Phase 1 Completed 31 enrolled Janssen Research & Development, LLC

Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of the study is to evaluate pharmacokinetics (PK) of ustekinumab in juvenile psoriatic arthritis (jPsA) and pediatric psoriasis (PsO).

Timeline

Start: 2022-05-24
Primary completion: 2024-01-26
Completion: 2024-01-26

Publications

Lam E, Berezny K, Bishop CJ, Lomax KG, Liva SG, Brunner HI, Paller AS, Diaz LZ, Lee LW, Rubin C, Carrasco R, Imundo L, Majlessi A, Smith V, Zhang R, Leu JH; U-POPS Study Group. Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS). Rheumatol Ther. 2026 Feb;13(1):265-278. doi: 10.1007/s40744-025-00820-3. Epub 2025 Dec 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ustekinumab	Monoclonal antibody	—	—

Indications